Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 80 years admitted to medicine and surgery services.~2. A known history of Type 2 Diabetes \> 1 month, receiving either diet alone, oral antidiabetic agents: sulfonylureas and metformin as monotherapy or in combination therapy (excluding DPP-4 inhibitors) or low-dose (≤ 0.6 units/kg/day) insulin therapy.~3. Subjects with a blood glucose \>140 mg and \< 400 mg/dL at time of randomization without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~Exclusion Criteria:~1. Age \< 18 or \> 80 years.~2. Subjects with increased BG concentration, but without a history of diabetes (stress hyperglycemia).~3. Subjects with a history of type 1 diabetes (suggested by BMI \< 25 requiring insulin therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria) \[46\].~4. Treatment with DPP4 inhibitor or Glucagon like peptide 1 (GLP1) analogs during the past 3 months prior to admission.~5. Acute critical illness or coronary artery bypass graft (CABG) surgery expected to require admission to a critical care unit.~6. Subjects with gastrointestinal obstruction or adynamic ileus or those expected to require gastrointestinal suction.~7. Medical or surgical patients expected to be kept NPO for \>24-48 hours after admission or after completion of surgical procedure.~8. Patients with clinically relevant pancreatic or gallbladder disease.~9. Patients with acute myocardial infarction, clinically significant hepatic disease or significantly impaired renal function (GFR \< 30 ml/min).~10. Treatment with oral or injectable corticosteroid = or \> prednisone 5 mg/per day.~11. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~12. Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + glargine (Hospital) (Type: EXPERIMENTAL): Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
- Basal bolus (Hospital) (Type: ACTIVE_COMPARATOR): Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
- Metformin and Sitagliptin (Type: EXPERIMENTAL): Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
- Metformin and sitagliptin + glargine 50% (Type: EXPERIMENTAL): Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
- Metformin and sitagliptin + glargine 80% (Type: EXPERIMENTAL): Patients with HbA1c \> 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).